| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reviews |
1 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, and
2 Tobacco Related Malignancies Program, University of Colorado Cancer Center and Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado
Fifteen % or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The current standard of care for patients with locally advanced or metastatic NSCLC is systemic chemotherapy with a two-drug combination regimen that includes a platinum agent. Although systemic chemotherapy reduces the rate of death attributable to lung cancer, disease progression is inevitable and dose-limiting toxicities restrict their use. New molecularly targeted therapies aim to inhibit specific pathways and key molecules implicated in tumor growth and progression while sparing normal cells. Several therapies, which target signal transduction pathways involved in angiogenesis, metastasis, and apoptosis, are in clinical development to treat lung cancer. Among these targeted therapies are the oral, small-molecule epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors gefitinib and erlotinib. Both therapies have been validated preclinically as new treatment approaches for NSCLC and have shown single-agent activity against advanced, chemorefractory NSCLC in clinical trials. This article focuses on the biology of the EGFR-TK signal transduction pathway, its role in the proliferation of solid tumors, and the rationale for the clinical development of EGFR-TK inhibitors. We also review clinical trials with EGFR-TK inhibitors in NSCLC and future directions of investigation with these targeted agents.
This article has been cited by other articles:
|
|
 |
|
  T. Tanaka, A. Munshi, C. Brooks, J. Liu, M. L. Hobbs, and R. E. Meyn Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity Clin. Cancer Res., February 15, 2008; 14(4): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Ling, T. Li, Z. Yuan, M. Haigentz Jr., T. K. Weber, and R. Perez-Soler Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27KIP1 Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines Mol. Pharmacol., August 1, 2007; 72(2): 248 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab Clin. Cancer Res., August 1, 2007; 13(15): 4597s - 4601s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Park, H. J. Jun, M. J. Cho, K. H. Cho, J. S. Lee, J. I. Zo, and H. Pyo Radiosensitivity Enhancement by Combined Treatment of Celecoxib and Gefitinib on Human Lung Cancer Cells. Clin. Cancer Res., August 15, 2006; 12(16): 4989 - 4999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Johnson and P. A. Janne Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4436s - 4440s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Toulany, U. Kasten-Pisula, I. Brammer, S. Wang, J. Chen, K. Dittmann, M. Baumann, E. Dikomey, and H. P. Rodemann Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair. Clin. Cancer Res., July 1, 2006; 12(13): 4119 - 4126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Alvarez, H. Greulich, W. R. Sellers, M. Meyerson, and D. A. Frank Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res., March 15, 2006; 66(6): 3162 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Thienelt, P. A. Bunn Jr, N. Hanna, A. Rosenberg, M. N. Needle, M. E. Long, D. L. Gustafson, and K. Kelly Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2005; 23(34): 8786 - 8793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Johnson, M. Cohen, R. Sridhara, Y.-F. Chen, G. M. Williams, J. Duan, J. Gobburu, B. Booth, K. Benson, J. Leighton, et al. Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen Clin. Cancer Res., September 15, 2005; 11(18): 6414 - 6421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Johnson and P. A. Janne Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer Cancer Res., September 1, 2005; 65(17): 7525 - 7529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Cohen, J. R. Johnson, Y.-F. Chen, R. Sridhara, and R. Pazdur FDA Drug Approval Summary: Erlotinib (Tarceva(R)) Tablets Oncologist, August 1, 2005; 10(7): 461 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Tsao, A. Sakurada, J.-C. Cutz, C.-Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, et al. Erlotinib in Lung Cancer -- Molecular and Clinical Predictors of Outcome N. Engl. J. Med., July 14, 2005; 353(2): 133 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Petty, K. H. Dragnev, V. A. Memoli, Y. Ma, N. B. Desai, A. Biddle, T. H. Davis, W. C. Nugent, N. Memoli, M. Hamilton, et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers Clin. Cancer Res., November 15, 2004; 10(22): 7547 - 7554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P-R Burgel and J A Nadel Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium Thorax, November 1, 2004; 59(11): 992 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Rose and R. Wild Therapeutic Synergy of Oral Taxane BMS-275183 and Cetuximab versus Human Tumor Xenografts Clin. Cancer Res., November 1, 2004; 10(21): 7413 - 7417. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
